{"id":"NCT04558918","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment","officialTitle":"A Randomized, Multicenter, Active-comparator Controlled, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult Patients With PNH and Residual Anemia, Despite Treatment With an Intravenous Anti-C5 Antibody.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-01-25","primaryCompletion":"2022-09-26","completion":"2023-03-06","firstPosted":"2020-09-22","resultsPosted":"2023-11-28","lastUpdate":"2024-10-09"},"enrollment":97,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Paroxysmal Nocturnal Hemoglobinuria (PNH)"],"interventions":[{"type":"DRUG","name":"LNP023","otherNames":["iptacopan"]},{"type":"DRUG","name":"Eculizumab","otherNames":[]},{"type":"DRUG","name":"Ravulizumab","otherNames":[]}],"arms":[{"label":"LNP023 200mg b.i.d.","type":"EXPERIMENTAL"},{"label":"Anti-C5 antibody","type":"ACTIVE_COMPARATOR"}],"summary":"This study was a multi-center, randomized, open-label, active comparator-controlled, parallel group study.\n\nThe purpose of this Phase 3 study in PNH patients presenting with residual anemia despite treatment with anti-C5 antibody, was to determine whether iptacopan is efficacious and safe for the treatment of PNH through demonstration of superiority of iptacopan compared to anti-C5 antibody treatment.","primaryOutcome":{"measure":"Marginal Proportion (Expressed as Percentages) of Participants With Sustained Increase in Hemoglobin Levels From Baseline of â‰¥ 2 g/dL in the Absence of Red Blood Cell Transfusions","timeFrame":"Baseline, hemoglobin between Day 126 and Day 168 and absence of transfusions between Day 14 and Day 168","effectByArm":[{"arm":"LNP023 200mg b.i.d.","deltaMin":82.3,"sd":null},{"arm":"Anti-C5 Antibody","deltaMin":2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":39,"countries":["United States","Brazil","Czechia","France","Germany","Italy","Japan","Netherlands","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["40694294","40447351","38477987"],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=2142"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":62},"commonTop":["COVID-19","Headache","Diarrhoea","Nasopharyngitis","Nausea"]}}